source
- GSK to begin Phase 3 trial of mRNA seasonal flu vaccine after strong Phase 2 resultsGSK announced it will start a Phase 3 study of its mRNA vaccine targeting seasonal influenza. The move follows Phase 2 data that showed the candidate produced higher immune responses than traditio…
- Novartis' Rhapsido shows safety edge and relapse reduction in Phase 3 multiple sclerosis trialsNovartis reported results from two identical Phase 3 studies of its BTK inhibitor Rhapsido in patients with multiple sclerosis. The trials showed the oral pill lowered the annualized relapse rate…